Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 May 31); and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 14).
"We are pleased to have virtual platforms such as ASCO20 and EHA25 to continue sharing important data with the scientific community in a timely manner," said Steven Stein, M.D., Chief Medical Officer, Incyte. "These data demonstrate the strength of our broad oncology portfolio and our partnerships; and reinforce our commitment to finding solutions that can help meet patients needs."
Key abstracts accepted by ASCO and EHA include:
ASCO Abstracts
Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, May 29, 2020, 8:00 AM ET.
Oral Presentations
Capmatinib in Patients with High-Level MET-Amplified Advanced Non-Small Cell Lung Cancer (NSCLC): Results from the Phase 2 GEOMETRY mono-1 Study (Abstract #9509, Session: MET Mutations: The Meat of the Matter)1
Interim Analysis (IA) of OPTIC: A Dose-Ranging Study of Three Ponatinib (PON) Starting Doses (Abstract #7502, Session: Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant)2
E-Poster Presentations
An Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib (PON) Phase 2 PACE Trial (NCT01207440) in Patients (pts) with Ph+ Leukemia (Abstract #7550, Session: Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant)2
Re-MIND Study: A Propensity Score-Based 1:1 Matched Comparison of Tafasitamab + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #8020, Session: Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia)3
Safety and Efficacy of Pemigatinib Plus Pembrolizumab Combination Therapy in Patients (pts) with Advanced Malignancies: Results from FIGHT-101, an Open-Label Phase 1/2 study (Abstract #3606, Session: Developmental TherapeuticsMolecularly Targeted Agents and Tumor Biology)
Capmatinib in Patients with METex14-Mutated or High-Level MET-Amplified Advanced Non-Small-Cell Lung Cancer (NSCLC): Results from Cohort 6 of the Phase 2 GEOMETRY mono-1 study (Abstract #9520, Session: Lung CancerNon-Small Cell Metastatic)1
Pan-Cancer Analysis of FGFR1-3 Genomic Alterations to Reveal a Complex Molecular Landscape (Abstract #3620, Session: Developmental TherapeuticsMolecularly Targeted Agents and Tumor Biology)
EHA Abstracts
Oral abstract presentations and e-posters accepted for presentation at EHA will be available on the on-demand Virtual Congress platform beginning Friday, June 12, 2020, at 8:30 AM CEST.
Oral Presentations
Addition of Parsaclisib, a PI3K inhibitor, in Patients with Suboptimal Response to Ruxolitinib (Rux): A Phase 2 Study in Patients (Pts) with Myelofibrosis (MF) (Abstract #S216, Session: Novel Therapies and Pitfalls in MPN)
Ruxolitinib Versus Best Available Therapy in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: Overall Response Rate by Baseline Characteristics in the Randomized Phase 3 REACH2 Trial (Abstract #S255, Session: Stem Cell Transplantation Clinical: Graft-Versus-Host Disease)1
GRAVITAS-301: A Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for Initial Treatment of Patients with Acute Graft-Versus-Host Disease (Abstract #S256, Session: Stem Cell Transplantation Clinical: Graft-Versus-Host Disease)
Interim Analysis from the OPTIC Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib (Abstract #S172, Session: Chronic Myeloid Leukemia (CML) Clinical)2
Re-MIND Study: Comparison of Tafasitamab + Lenalidomide (L-Mind) vs Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Abstract #S238, Aggressive Lymphomas: Observational Studies)3
Story continues
E-Poster Presentations
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Ruxolitinib Exposed vs Unexposed (Abstract #EP1124, Session: Myeloproliferative Neoplasms Clinical)
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Pre- vs Post-Ruxolitinib Approval (Abstract # EP1120, Session: Myeloproliferative Neoplasms Clinical)
Machine-Learning to Predict Hydroxyurea (HU) Failure and Incidence of Thromboembolic Events (TEs) with HU vs Ruxolitinib Switch Therapy in Polycythemia Vera Patients (Abstract #EP1117, Session: Myeloproliferative Neoplasms Clinical)1
Patient-Reported Physical, Emotional and Economic Impact of Myeloproliferative Neoplasms in an Expansion of the MPN Landmark Survey (Abstract #EP1112, Session: Myeloproliferative Neoplasms Clinical)1
Ruxolitinib in PV Patients Resistant and/or Intolerant to Hydroxyurea: Interim Analysis of a European Multi-Centric Observational Study (Abstract #EP1115, Session: Myeloproliferative Neoplasms Clinical)1
Treatment and Disease Management Practices in Patients with MPNs in 6 Countries: An Expansion of the MPN Landmark Survey (Abstract #EP1123, Session: Myeloproliferative Neoplasms Clinical)1
Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Phase 2 PACE Trial of Ponatinib in Philadelphia Chromosome Positive (Ph+) Leukemia (Abstract #EP759, Session: Chronic Myeloid Leukemia (CML) Clinical)2
The RealLife Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Deep Molecular Responses in a Cohort of 75 TKI-Resistant or Intolerant patients with CML (Abstract #EP765, Session: Chronic Myeloid Leukemia (CML) Clinical)
Combination of Tafasitamab (MOR208) and Lenalidomide Enhances Tumor Cell Death of B-cell Lymphoma in Vitro (Abstract #EP1343, Session: Lymphoma Biology & Translational Research)3
Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (Mor208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Abstract #EP1201, Session: Aggressive Non-Hodgkin Lymphoma - Clinical)3
Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells After Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data (Abstract #EP671, Chronic Lymphocytic Leukemia and Related Disorders - Biology & Translational Research)3
For full session details and data presentation listings, please see the ASCO20 (https://meetinglibrary.asco.org) and EHA25 (https://learningcenter.ehaweb.org/eha) online programs.
About IncyteIncyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking StatementsExcept for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Companys or partner companys ongoing clinical development pipeline, and whether or when any development compounds will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO and EHA meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Companys current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Companys dependence on its relationships with its collaboration partners; the efficacy or safety of the Companys products and the products of the Companys collaboration partners; the acceptance of the Companys products and the products of the Companys collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Companys reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended March 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.
1Novartis-sponsored; 2Takeda-sponsored; 3MorphoSys-sponsored
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005695/en/
Contacts
Media Catalina Loveman+1 302 498 6171cloveman@incyte.com
Investors Michael Booth, DPhil+1 302 498 5914mbooth@incyte.com
Go here to see the original:
Data from Incytes Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings - Yahoo Finance
- Bone Marrow and Stem Cell Transplants - Christiana Care ... [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Stem Cell Doctors, Physician Team, Our Doctors [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- California Stem Cell Report: California Stem Cell Agency ... [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- Stem Cell Companies - A Comprehensive Overview [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- Core mechanism for root growth identified [Last Updated On: August 25th, 2014] [Originally Added On: August 25th, 2014]
- Delaware Stem Cell Treatment | Stem Cell Treatments [Last Updated On: September 9th, 2014] [Originally Added On: September 9th, 2014]
- Can a bodys own stem cells help heal a heart? [Last Updated On: October 19th, 2014] [Originally Added On: October 19th, 2014]
- The California Cloning and Stem Cell Laws [Last Updated On: December 27th, 2014] [Originally Added On: December 27th, 2014]
- IPS Stem Cells: New Ethical Quandaries - Santa Clara ... [Last Updated On: December 27th, 2014] [Originally Added On: December 27th, 2014]
- Stem-cell battles: Stem-cell research in the USA is facing ... [Last Updated On: April 9th, 2015] [Originally Added On: April 9th, 2015]
- DSU AgDiscovery 2015 - Investing in the Future of American ... [Last Updated On: June 1st, 2015] [Originally Added On: June 1st, 2015]
- De-Differentiation of Somatic Cells to a Pluripotent State ... [Last Updated On: June 29th, 2015] [Originally Added On: June 29th, 2015]
- Alpine Rose Leaf Extract for Environmental Protection for ... [Last Updated On: October 1st, 2015] [Originally Added On: October 1st, 2015]
- Efficient Differentiation of Mouse Embryonic Stem Cells ... [Last Updated On: October 1st, 2015] [Originally Added On: October 1st, 2015]
- Stem Cells - Eppendorf [Last Updated On: October 2nd, 2015] [Originally Added On: October 2nd, 2015]
- Home | www.papoutsakis.org [Last Updated On: October 4th, 2015] [Originally Added On: October 4th, 2015]
- University of Delaware Chemical Engineering [Last Updated On: October 31st, 2015] [Originally Added On: October 31st, 2015]
- Delaware (Stem Cell) - what-when-how [Last Updated On: November 3rd, 2016] [Originally Added On: November 3rd, 2016]
- Lions LB Paul Worrilow gave stem cells to anonymous leukemia patient - Detroit Free Press [Last Updated On: March 11th, 2017] [Originally Added On: March 11th, 2017]
- Lions LB Paul Worrilow Making A Difference On And Off The Field - FanRag Sports (blog) [Last Updated On: July 2nd, 2017] [Originally Added On: July 2nd, 2017]
- Detroit Lions' Paul Worrilow has beaten odds, inspires others to help - Detroit Free Press [Last Updated On: July 2nd, 2017] [Originally Added On: July 2nd, 2017]
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Delaware First Media [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Regenerative Cell Therapy - Delaware Integrative Medicine [Last Updated On: June 22nd, 2018] [Originally Added On: June 22nd, 2018]
- Stem Cell Doctors Delaware, Stem cell injections, Stem ... [Last Updated On: October 14th, 2018] [Originally Added On: October 14th, 2018]
- Stem Cell Therapy | Regenerative Delaware [Last Updated On: February 22nd, 2019] [Originally Added On: February 22nd, 2019]
- Regenerative Cell Treatment &Therapy - Delaware ... [Last Updated On: February 22nd, 2019] [Originally Added On: February 22nd, 2019]
- Stem Cell therapy Wilmington Delaware 19810 [Last Updated On: February 27th, 2019] [Originally Added On: February 27th, 2019]
- Stem Cell therapy Newark Delaware 19725 [Last Updated On: February 27th, 2019] [Originally Added On: February 27th, 2019]
- SignalRx [Last Updated On: March 22nd, 2019] [Originally Added On: March 22nd, 2019]
- Westfield High School Principal Derrick Nelson was 'gift ... [Last Updated On: May 16th, 2019] [Originally Added On: May 16th, 2019]
- Stem Cell therapy Lewes Delaware 19958 [Last Updated On: September 14th, 2019] [Originally Added On: September 14th, 2019]
- Could Fate Therapeutics, Inc. (FATE) Recover After Forming a Bearish Head & Shoulders Pattern? - The Altcoin Mercury [Last Updated On: September 25th, 2019] [Originally Added On: September 25th, 2019]
- What Will Happen to Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) Next? The Stock Has Increase in Shorts - The Lamp News [Last Updated On: October 26th, 2019] [Originally Added On: October 26th, 2019]
- From inspiration to innovation | UDaily - UDaily [Last Updated On: November 14th, 2019] [Originally Added On: November 14th, 2019]
- Global Stem Cell Therapy Market 2019-2025 Analyzed by Business Growth, Development Factors, Applications, and Future Prospects - Technology Magazine [Last Updated On: December 17th, 2019] [Originally Added On: December 17th, 2019]
- Gore, Mayo Clinic team up to deliver breakthrough medical therapies - Plastics Today [Last Updated On: December 17th, 2019] [Originally Added On: December 17th, 2019]
- First CAR-T cell cancer therapy patient in Delaware - Dover Post [Last Updated On: February 10th, 2020] [Originally Added On: February 10th, 2020]
- Stem Cell therapy Middletown Delaware 19709 [Last Updated On: February 10th, 2020] [Originally Added On: February 10th, 2020]
- 'Billion Dollar Burger' Asks: What Is Meat? - Delaware First Media [Last Updated On: June 17th, 2020] [Originally Added On: June 17th, 2020]
- Bone Marrow and Stem Cell Transplants ChristianaCare [Last Updated On: June 20th, 2020] [Originally Added On: June 20th, 2020]
- Rock snot discovered in another Pennsylvania waterway - pennlive.com [Last Updated On: September 12th, 2020] [Originally Added On: September 12th, 2020]
- MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of... [Last Updated On: August 31st, 2021] [Originally Added On: August 31st, 2021]
- Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults... [Last Updated On: August 31st, 2021] [Originally Added On: August 31st, 2021]
- Why Eraser Enzymes Go Wrong and Lead to Cancer - SciTechDaily [Last Updated On: December 10th, 2021] [Originally Added On: December 10th, 2021]
- Microscopy Devices Market Competitive Insights and Precise Outlook 2021-2028 Industrial IT - Industrial IT [Last Updated On: June 4th, 2022] [Originally Added On: June 4th, 2022]
- Neoantigen Targeted Therapies Market Analysis and Opportunity Assessment up to 2027 - BioSpace [Last Updated On: June 4th, 2022] [Originally Added On: June 4th, 2022]
- Transplant Diagnostic Market: Increase in Number of Cancer & Blood Disorder Patients to Drive the Market - BioSpace [Last Updated On: July 11th, 2022] [Originally Added On: July 11th, 2022]
- Orthobiologics Market is Predicted to Expand at a CAGR of 4.7% during the Forecast Period, notes TMR Study - GlobeNewswire [Last Updated On: July 11th, 2022] [Originally Added On: July 11th, 2022]
- Cell Line Development Market: Increase in Prevalence of Cancer and Other Chronic Diseases to Drive the Market - BioSpace [Last Updated On: July 11th, 2022] [Originally Added On: July 11th, 2022]
- Antibody Therapy Market Propels at a Robust CAGR of 13.2% due to Rising Cancer and Other Chronic Disease Prevalence Future Market Insights, Inc. -... [Last Updated On: July 19th, 2022] [Originally Added On: July 19th, 2022]
- Immunoglobin Products Market to Witness Comprehensive Growth by 2031 - BioSpace [Last Updated On: July 19th, 2022] [Originally Added On: July 19th, 2022]
- Lipid Disorder Treatment Market is Projected to Experience Promising Growth Opportunities in the Forthcoming Years - BioSpace [Last Updated On: July 27th, 2022] [Originally Added On: July 27th, 2022]
- Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 - PR Newswire UK [Last Updated On: July 27th, 2022] [Originally Added On: July 27th, 2022]
- Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema - Travel Adventure Cinema [Last Updated On: July 27th, 2022] [Originally Added On: July 27th, 2022]
- Drug Discovery Services Market is Expected to Witness Significant Growth between 20212031 - BioSpace [Last Updated On: July 27th, 2022] [Originally Added On: July 27th, 2022]
- Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News [Last Updated On: August 5th, 2022] [Originally Added On: August 5th, 2022]
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Trends, Competitive Landscape and Regional Insights to 2031 - BioSpace [Last Updated On: August 14th, 2022] [Originally Added On: August 14th, 2022]
- Multiphoton Microscopy Market Insights, New Innovations, Research and Growth Factor till 2031 - BioSpace [Last Updated On: August 14th, 2022] [Originally Added On: August 14th, 2022]
- Regenerative Therapies Market 2018 By Emerging Trends, Industry Share, Regional Overview and SWOT Analysis till 2026 - Digital Journal [Last Updated On: August 22nd, 2022] [Originally Added On: August 22nd, 2022]
- Cell Banking Outsourcing Market is Driven by Rising Number of Stem Cell Therapies across the Globe - BioSpace [Last Updated On: September 8th, 2022] [Originally Added On: September 8th, 2022]
- Virology Market Growth Prospects, Trends and Forecast up to 2030 - BioSpace [Last Updated On: September 8th, 2022] [Originally Added On: September 8th, 2022]
- DiMethyl Sulfoxide (DMSO) Market to Touch US$ 838.6 Million in 2032 Owing to its Widespread Application in End-Use Industries & Anti-Inflammatory... [Last Updated On: September 16th, 2022] [Originally Added On: September 16th, 2022]
- External Beam Radiation Therapy Market: Growing Awareness about Early Detection and Diagnosis of various Cancer Types to Drive the Market - BioSpace [Last Updated On: September 16th, 2022] [Originally Added On: September 16th, 2022]
- Stem Cells Market is Expected to Grow with High Probability Business Opportunity by 2028 - Digital Journal [Last Updated On: October 4th, 2022] [Originally Added On: October 4th, 2022]
- Orthobiologics Market to Receive Overwhelming Hike in Revenues by 2031 - openPR [Last Updated On: October 13th, 2022] [Originally Added On: October 13th, 2022]
- PRP and PRF in Cosmetics Market Growth Opportunities Analysis Report - openPR [Last Updated On: October 13th, 2022] [Originally Added On: October 13th, 2022]
- Cell & Tissue Preservation Market Size will Observe Lucrative Surge by the End 2031 - openPR [Last Updated On: October 13th, 2022] [Originally Added On: October 13th, 2022]
- Mice Model Technologies Market Outlook, Competitive Landscape and Forecasts to 2031 - openPR [Last Updated On: October 13th, 2022] [Originally Added On: October 13th, 2022]
- Japan Stem Cells Market to be at Forefront by 2028 [Last Updated On: November 24th, 2022] [Originally Added On: November 24th, 2022]